Can Sun Pharma stabilize margins while specialty medicines gain traction?
Q1 revenue growth outpaced profit growth, signaling margin pressure. Analysts expect on-plan revenue but watch closely for EBITDA recovery as specialty launches (UNLOXCYT®, LEQSELVI®) ramp—and whether US formulations can stabilize.
Sun Pharma opens Q2 FY27 (ended September 30, 2026) under analyst scrutiny on one theme: can the company stabilize or expand EBITDA margins after Q1's compression? Headline revenue growth is on-plan at 9–10% YoY—analyst consensus of 23 analysts pegs Q2 revenue at ~₹15,825 Cr, a solid print. But Q1 showed the tension: revenue jumped 10.5% YoY, yet adjusted net profit inched just 3.1% forward. EBITDA margin slipped to 28.9% from 31.1% a year prior, a 220 basis-point headwind. The Street remains bullish (27 of 31 buy-rated, avg target ₹2,148), but the real test is whether specialty launches and margin discipline can reignite profit growth this quarter.
The on-plan expectations
~₹15,825 Cr
Analyst consensus (23 analysts, ±9.3% YoY growth); India formulations likely +10–14%, offset partly by US headwinds
28.9–29.5%
Q1 was 28.9%; if stable or recovered, earnings growth follows. Compression would echo Q1's concern and pressure valuations
Mid-to-high single digits YoY
Q1 was +3.1%, a miss vs revenue growth. Q2 profit leverage will hinge on gross margin and cost control
Early-stage ramp
UNLOXCYT® (cancer), LEQSELVI® (alopecia) regulatory wins recent; full revenue impact likely Q3+ as inventory/adoption builds
A strong print would see: revenue at or above ₹15,900 Cr, EBITDA margin recovered to 29.5%+ (signaling cost/manufacturing discipline), and guidance reaffirmed or lifted for FY27. Specialty medicines beginning to flex in India and international markets would show runway. A weak print would show: revenue missing consensus (sub-₹15,700 Cr), EBITDA margin compressed further below 28.9%, and any reduction in specialty or US export expectations. Margin miss would signal structural headwinds (pricing, input costs, or launch spending) that outlast one quarter.
Is the company on track?
Q1 FY27 showed the tightrope: revenue +10.5% YoY, but adjusted profit +3.1%—a 7-point spread that raised eyebrows. EBITDA margin of 28.9% remained above consensus (28.2%), but the year-on-year slip from 31.1% flags input cost or manufacturing intensity. For Q2, the bar is demonstrating that Q1 was a trough (likely one-time R&D/manufacturing spends) and that the growth trajectory (especially in specialty) can re-lever profit. India formulations (36% of sales) grew 16% in Q1 and should sustain double-digit momentum. US formulations declined 9.7% YoY and remain a question mark—whether stabilization arrives in Q2 or bleeds into H2 will shape confidence in FY27 guidance. Full-year, Sun Pharma targets mid-single-digit growth; Q2 on-plan execution keeps that trajectory credible.
What the Street says
Since Q1 FY27: the filings scan
1 · UNLOXCYT® regulatory momentum (Oct 20–24)
NCCN Category 2A preferred designation for advanced cutaneous squamous-cell carcinoma; long-term efficacy/safety data presented at ESMO Congress (Oct 24). Sets stage for revenue contribution, likely Q3+ as commercial ramp and adoption build. Early positive signal for specialty franchise.
2 · LEQSELVI® sustained efficacy (Oct 1)
Two-year sustained efficacy and safety data in severe alopecia areata presented at European Academy of Dermatology. Strengthens label and patient confidence; commercial contribution still early. Specialty foundation broadening.
3 · INR 10,000 Cr NCD issuance (Oct 12)
Board approved private placement of listed, rated non-convertible debentures. Signals capital-raise for Organon acquisition (closing early 2027) and/or debt refinance. No immediate P&L impact, but shows management confidence and liquidity planning.
4 · Lerodalcibep licensing deal (Sep 28)
Global (ex-US/China) licensing and manufacturing agreement with LIB Therapeutics for PCSK9 inhibitor. Upfront royalty and milestone economics not disclosed, but adds non-dilutive revenue stream and demonstrates specialty-asset base.
5 · Promoter reclassification (Sep 26)
Shareholders approved reclassification of certain individuals from 'Promoter Group' to 'Public' category. No operational impact; routine compliance matter. FII ownership holding steady at ~14.5%.
Flag: No insider/promoter pledges or block deals worth flagging. Bulk activity in June (₹1,868/share, institutional GPIF transactions) was orderly and doesn't signal distress. No surprises on governance or compliance fronts.
What to watch on result day
1 · EBITDA margin recovery (or further miss)
If margin rebounds to 29.5%+ or holds 28.9%, confidence in cost control and FY27 guidance revives. If below 28.7%, it signals structural headwinds (raw materials, manufacturing intensity, or R&D spend) that may pressure multiple. This is THE metric.
2 · US formulations stabilization
Q1 saw -9.7% YoY decline. Consensus expects flattish or low-single-digit growth in Q2. Any stabilization (growth ≥0%) or guidance that limits future declines would reassure. Continued mid-digit declines would invite downgrades.
3 · Specialty medicines: early revenue signals & FY27 guidance
UNLOXCYT® and LEQSELVI® are regulatory wins. Q2 revenue (if any) will be light, but guidance commentary on ramp trajectory and peak-sales expectations (next 2–3 years) will set the long-term valuation tone. Street is betting on specialty re-rating; clarity matters.
Sun Pharma's Q2 FY27 report lands October 30 with analyst consensus priced in: ~₹15,825 Cr revenue, modest profit growth, margin stability watch. The stock sits ₹1,748 as of Oct 23, 2% below consensus target ₹2,148 and trading below all major SMAs—sentiment is cautious despite the buy-rating chorus. The real test is not the headline number but the *trajectory*: does Q2 show that Q1's margin compression was a speed bump (R&D, manufacturing refit, inventory build) or a signal of structural headwinds? Can specialty medicines (UNLOXCYT®, LEQSELVI®) begin to prove the investment thesis? And will US formulations stabilize? Margins recovered and specialty growth tracked would confirm the bull case. Margins miss again and US remains under pressure would prompt multiple reset. On balance, the Street is positioned for execution; Q2 results will sort conviction from hope.
Sun Pharma Q2FY27: PAT -36% YoY on one-offs, adjusted PAT flat vs 12% revenue growth
PAT -36.4% YoY · revenue +11.9% · margins compressing
₹16,198.71 Cr
+11.9% YoY
₹1,988.53 Cr
-36.4% YoY
11.9%
-9pp YoY
₹8.3
Sun Pharma's consolidated (primary) PAT fell 36.4% YoY to ₹1,988.5 Cr (-31.5% QoQ from ₹2,901.2 Cr), even as consolidated revenue grew 11.8% YoY and 5.9% QoQ to ₹16,198.7 Cr. The gap is almost entirely a one-off: the quarter carries a ₹1,268.8 Cr pre-tax exceptional charge — ₹346.2 Cr of Organon acquisition diligence/legal/financing costs and a ₹922.7 Cr settlement of the Taro US antitrust pricing litigation — against a tax credit of ₹95.3 Cr. Stripping that out, management's adjusted net profit was ₹3,162 Cr, up just 1.2% YoY, meaning even on a clean basis profit growth badly lagged the 11.8% revenue growth. Standalone PAT was ₹871.3 Cr with no exceptional items at all, underscoring that both the growth and the one-off hit sit in the overseas/subsidiary layer consolidated into the group numbers.
Q2 FY-2027 vs prior quarters
The margin bridge explains the adjusted-profit shortfall: EBITDA margin was 29.3% (₹4,743.9 Cr), down roughly 200 bps from 31.3% a year ago, though up about 180 bps sequentially from 27.5% in Q1FY27. The YoY compression traces to US formulations, where sales fell 8.2% YoY to $455 Mn (27% of consolidated sales) — a continuation of the slowdown flagged after Q1. That weakness was partly offset by India formulations, up 17.3% YoY to ₹5,552.3 Cr (34.5% of sales, Sun Pharma's #1 India market share now at 8.6% per Pharmarack), Global Innovative Medicines up 6.9% YoY to $356 Mn, Emerging Markets up 7.6% to $350 Mn, and RoW up 3.1% to $241 Mn. R&D spend was ₹778.4 Cr, 4.8% of sales — below the 6-7% intensity management had guided to in the prior concall, a shortfall rather than a beat on that specific line.
The stock went into the print at ₹1,795.1, down 3.7% over the past month of trading.
For context: revenue is at a 6-quarter high.
FY27 high single-digit revenue growth maintained (not raised despite Q1 10.5% beat). R&D 6–7% of sales as guided. ETR 27.8% expected to hold until Organon closes Q4 FY27. No numeric margin guidance provided.
— This quarter: beat
No reliable street/consensus estimate for this specific quarter could be confirmed via search, so vsStreet is unknown rather than assumed. Against the company's own prior guidance (FY27 high single-digit revenue growth, maintained even after Q1's 10.5% beat), this quarter's 11.8% YoY growth keeps running well ahead of that bar. The effective tax rate on pre-exceptional profit works out to about 28.3%, close to the 27.8% guided to hold until the Organon deal closes in Q4FY27 — in line. Corporate activity this quarter ties directly to that deal: the company allotted ₹7,816 Cr of non-convertible debentures on October 26, 2026, part of the financing for the ~$11.75 Bn Organon acquisition, whose integration management says is progressing on plan with regulatory approvals secured in most regions. Management's press release framed the quarter around India/EM/RoW momentum and the US approval of Ilumya for psoriatic arthritis; the framing is accurate on topline drivers but doesn't address the margin compression and R&D undershoot the numbers show.
W1
US formulation sales trajectory after an 8.2% YoY decline to $455 Mn this quarter — watch for stabilization in Q3FY27
W2
R&D spend ramp toward the guided 6-7% of sales range, up from this quarter's 4.8% (₹778.4 Cr)
W3
Effective tax rate holding near the guided 27.8% (currently ~28.3% on pre-exceptional profit) as the Organon acquisition closes in Q4FY27